Paradoxically, a completely deregulated activity of GSK-3β according to modifications in the differential phosphorylation of S9 and Y216 residues was seen in gastrointestinal cancers (Mai et al. 2009) and glioblastoma (Miyashita et al. 2009) compared to "healthy" cells. This evidence concerns the gene GSK3B and glioblastoma.